• Problems of diagnosis and choice of antifungal drugs for vulvovaginal candidiasis: practical advice from the perspective of evidence-based medicine

Problems of diagnosis and choice of antifungal drugs for vulvovaginal candidiasis: practical advice from the perspective of evidence-based medicine

HEALTH OF WOMAN. 2016.5(111):26–28
 

Problems of diagnosis and choice of antifungal drugs for vulvovaginal candidiasis: practical advice from the perspective of evidence-based medicine


Anfilova M. R.

Vinnitsa national medical University M. I. Pirogov


The article presents a review of the literature and international clinical guidelines on the management of vulvovaginal candidiasis. Based on current scientific evidence, we can conclude that the basic rules in the diagnosis and treatment of vulvovaginal candidiasis is a careful history taking, examination to determine the type and severity of the disease and the mandatory diagnostics pathogen bacteriological and molecular biological method with definition of sensitivity to antifungal drugs, especially when recurrent form. In the process of selecting treatment tactics, a particular drug and its route of administration should take into account the position of evidence-based medicine and compliance to meet today’s requirements.


Key words: vulvovaginal candidiasis, diagnosis, treatment, itraconazole, compliance.


REFERENCES

1. Akhtar S, Masood S, Tabassum S, Rizvi DA. 2012. Efficacy of itraconazole versus fluconazole in vaginal candidiasis. J. Pak. Med. Assoc. 62;10:1049–52. PMid:23866445

2. Allen D, Wilson D, Drew R, Perfect J. 2015. Azole antifungals: 35 years of invasive fungal infection management. Expert. Rev. Anti. Infect. Ther. 13;6:787–98. http://dx.doi.org/10.1586/14787210.2015.1032939; PMid:25843556

3. Cassone A. 2014. Vulvovaginal Candida albicans infections: pathogenesis, immunity and vaccine prospects. BJOG. 23;8:31–34.

4. Peter G Pappas, Carol A Kauffman, David R Andes. 2015. Clinical practice guidelines for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 15:35–36. http://dx.doi.org/10.1093/cid/civ933

5. Mikamo H, Kawazoe K, Sato Y at al. 1998. Comparative study on the effectiveness of antifungal agents in different regimens against vaginal candidiasis. Chemotherapy. 44;5:364–8. http://dx.doi.org/10.1159/000007136

6. Arendrup MC, Meletiadis J, Mouton JW at al. 2016, Feb. 3. EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents. Clin. Microbiol. Infect. pii: S1198-743X(16)00077-X. http://dx.doi.org/10.1016/j.cmi.2016.01.017. Epub ahead of print.

7. Ilkit M, Guzel AB. 2011. The epidemiology, pathogenesis, and diagnosis of vulvovaginal candidosis: a mycological perspective. Crit. Rev. Microbiol. 37;3:250–61. http://dx.doi.org/10.3109/1040841X.2011.576332; PMid:21599498

8. Jackie Sherrard1, Gilbert Donders, David White. 2011. European (IUSTI/WHO) Guideline on the Management of Vaginal Discharge.

9. Jilek P, Spasek J et al. 2007. Factors associated with recurrent vulvovaginal candidiasis dietary intake, clotting, sexual activities, personal hygiene, antibiotic use and allergies. 3rd Trends in Medical Mycology. Turin:99.

10. Julie van Schalkwyk, Mark H Yudin. 2015. Vulvovaginitis: Screening for and Management of Trichomoniasis, Vulvovaginal Candidiasis, and Bacterial Vaginosis. J. Obstet. Gynaecol. Can. 37;3:266–274. http://dx.doi.org/10.1016/S1701-2163(15)30316-9

11. Nguyen Y, Lee A, Fischer G. 2016, Jun 2. Management of chronic vulvovaginal candidiasis: a long term retrospective study. Australas. J. Dermatol. doi: 10.1111/ajd.12497. Epub ahead of print. http://dx.doi.org/10.1111/ajd.12497

12. Nurbhai M, Grimshaw J, Watson M et al. 2007, Oct 17. Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). Cochrane Database Syst. Rev. (4):CD002845. http://dx.doi.org/10.1002/14651858.cd002845.pub2

13. Sobel JD. 2014. Factors involved in patient choice of oral or vaginal treatment for vulvovaginal candidiasis. Pat. Pref. Adheren. 8:31–34.

14. Sonja A Rasmussen, Charlotte K Kent, Christine G. 2015. Casey Sexually Transmitted Diseases Treatment Guidelines, 2015. MMWR Recomm Rep. 64;3:75–78.